Research programme: CC-chemokine receptor 3 antagonists - Merck

Drug Profile

Research programme: CC-chemokine receptor 3 antagonists - Merck

Alternative Names: CCR3 chemokine receptor antagonists research programme - Merck & Co

Latest Information Update: 29 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 29 Aug 2011 Discontinued - Preclinical for Allergic rhinitis in USA (unspecified route)
  • 29 Aug 2011 Discontinued - Preclinical for Asthma in USA (unspecified route)
  • 12 Jan 2006 No development reported for asthma and allergic rhinitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top